shenzhen salubris pharmaceuticals co., ltd.-凯发官网首页

news & trends

• 262022-04

  teriparatide injection (xinfutai pro®) for osteoporosis approved for commercialization

• 092022-03

  salubris biotherapeutics announces $32 million financing to advance novel complex biologics for cardiovascular, oncology, and neurodegenerative diseases

• 042022-03

  nmpa approves clinical trials with sal0114 tablets for ad agitation

• 172022-02

  salubris announces clinical trial approval of sal0114 tablet – potential clinical depression treatment candidate

• 172022-02

  completion of clinical enrollment for phase iii clinical trial of sal0107 project – potential hypertension treatment candidate

• 212021-06

  allisartan isoproxil indapamide sustained-release tablets was approved for clinical trials

  recently, salubris received the notice of approval of clinical trials approved and issued by national medical products administration, which means that salubris was approved to carry out clinical trials of allisartan isoproxil indapamide sustained-re